Trending Stock News

Ppl (PPL) Stock Value Declined While Sun Life Financial Lifted Holding; As Ptc Therapeutics Cmn (PTCT) Market Valuation Rose, Holder Great Point Partners Raised Its Holding

PPL Corporation (NYSE:PPL) Logo

Sun Life Financial Inc increased its stake in Ppl Corp (PPL) by 144.94% based on its latest 2017Q4 regulatory filing with the SEC. Sun Life Financial Inc bought 22,916 shares as the company’s stock declined 10.38% with the market. The institutional investor held 38,727 shares of the central company at the end of 2017Q4, valued at $1.20M, up from 15,811 at the end of the previous reported quarter. Sun Life Financial Inc who had been investing in Ppl Corp for a number of months, seems to be bullish on the $19.50B market cap company. The stock increased 0.68% or $0.19 during the last trading session, reaching $28.08. About 4.66M shares traded. PPL Corporation (NYSE:PPL) has declined 25.72% since April 24, 2017 and is downtrending. It has underperformed by 37.27% the S&P500.

Jeffrey Jay increased its stake in Ptc Therapeutics Inc. Cmn (PTCT) by 136.04% based on its latest 2017Q4 regulatory filing with the SEC. Great Point Partners Llc bought 625,800 shares as the company’s stock rose 91.83% while stock markets declined. The hedge fund run by Jeffrey Jay held 1.09 million shares of the health care company at the end of 2017Q4, valued at $18.11 million, up from 460,000 at the end of the previous reported quarter. Great Point Partners Llc who had been investing in Ptc Therapeutics Inc. Cmn for a number of months, seems to be bullish on the $1.21B market cap company. The stock decreased 0.76% or $0.2 during the last trading session, reaching $26.03. About 481,971 shares traded. PTC Therapeutics, Inc. (NASDAQ:PTCT) has risen 274.65% since April 24, 2017 and is uptrending. It has outperformed by 263.10% the S&P500.

Among 12 analysts covering PTC Therapeutics (NASDAQ:PTCT), 4 have Buy rating, 2 Sell and 6 Hold. Therefore 33% are positive. PTC Therapeutics had 40 analyst reports since July 31, 2015 according to SRatingsIntel. The stock of PTC Therapeutics, Inc. (NASDAQ:PTCT) has “Hold” rating given on Wednesday, March 7 by RBC Capital Markets. RBC Capital Markets maintained it with “Outperform” rating and $56 target in Friday, October 16 report. As per Thursday, October 26, the company rating was downgraded by Bank of America. The rating was maintained by J.P. Morgan with “Hold” on Tuesday, September 26. The rating was initiated by Jefferies on Friday, October 23 with “Hold”. As per Tuesday, August 25, the company rating was initiated by Citigroup. As per Tuesday, February 23, the company rating was downgraded by JP Morgan. The firm has “Outperform” rating given on Friday, October 16 by Oppenheimer. The rating was maintained by Wedbush on Wednesday, February 24 with “Outperform”. RBC Capital Markets maintained the stock with “Hold” rating in Wednesday, July 5 report.

Great Point Partners Llc, which manages about $935.83 million and $586.07M US Long portfolio, decreased its stake in Myovant Sciences Ltd Cmn by 67,478 shares to 160,530 shares, valued at $2.03M in 2017Q4, according to the filing. It also reduced its holding in Rigel Pharmaceuticals Inc Cmn (NASDAQ:RIGL) by 1.22M shares in the quarter, leaving it with 7.89M shares, and cut its stake in Arena Pharmaceuticals Inc. Cmn.

Investors sentiment decreased to 0.98 in Q4 2017. Its down 0.73, from 1.71 in 2017Q3. It is negative, as 23 investors sold PTCT shares while 35 reduced holdings. 23 funds opened positions while 34 raised stakes. 35.45 million shares or 7.80% more from 32.89 million shares in 2017Q3 were reported. Guggenheim Lc owns 86,908 shares for 0% of their portfolio. Bnp Paribas Arbitrage has invested 0% in PTC Therapeutics, Inc. (NASDAQ:PTCT). Tower Limited Liability Corp (Trc) accumulated 1,413 shares or 0% of the stock. Wells Fargo & Com Mn owns 76,157 shares. Natl Bank Of New York Mellon reported 0% in PTC Therapeutics, Inc. (NASDAQ:PTCT). Blackrock Incorporated accumulated 3.09M shares. Chicago Equity Lc, a Illinois-based fund reported 17,770 shares. New York State Common Retirement Fund has 41,800 shares. Spark Inv Ltd Liability Com owns 1.04 million shares or 0.93% of their US portfolio. Brandywine Glob Inv Ltd Co has invested 0% in PTC Therapeutics, Inc. (NASDAQ:PTCT). Ameritas Prtnrs holds 0% of its portfolio in PTC Therapeutics, Inc. (NASDAQ:PTCT) for 3,416 shares. Matarin Capital Limited Co owns 16,587 shares for 0.02% of their portfolio. Royal State Bank Of Canada owns 0% invested in PTC Therapeutics, Inc. (NASDAQ:PTCT) for 729 shares. Kerrisdale Advisers Ltd Liability Corp stated it has 35,000 shares. Wellington Mngmt Grp Inc Limited Liability Partnership stated it has 0% in PTC Therapeutics, Inc. (NASDAQ:PTCT).

Since January 3, 2018, it had 0 buys, and 4 selling transactions for $61,523 activity. Utter Christine Marie also sold $7,280 worth of PTC Therapeutics, Inc. (NASDAQ:PTCT) shares. Peltz Stuart Walter also sold $40,207 worth of PTC Therapeutics, Inc. (NASDAQ:PTCT) on Friday, January 5.

Among 14 analysts covering PPL Corporation (NYSE:PPL), 7 have Buy rating, 1 Sell and 6 Hold. Therefore 50% are positive. PPL Corporation had 43 analyst reports since August 5, 2015 according to SRatingsIntel. Jefferies maintained it with “Hold” rating and $39.5000 target in Tuesday, June 20 report. On Friday, February 23 the stock rating was maintained by SunTrust with “Buy”. Evercore downgraded it to “Hold” rating and $36 target in Monday, February 8 report. RBC Capital Markets maintained the shares of PPL in report on Sunday, October 29 with “Hold” rating. As per Tuesday, March 6, the company rating was upgraded by RBC Capital Markets. The stock of PPL Corporation (NYSE:PPL) earned “Hold” rating by Jefferies on Wednesday, August 10. Deutsche Bank upgraded the shares of PPL in report on Thursday, January 18 to “Buy” rating. Macquarie Research downgraded the shares of PPL in report on Tuesday, December 19 to “Underperform” rating. The rating was downgraded by Jefferies to “Hold” on Thursday, July 14. On Tuesday, November 22 the stock rating was downgraded by Bank of America to “Neutral”.

Sun Life Financial Inc, which manages about $976.54 million US Long portfolio, decreased its stake in Vanguard Index Fds (VTI) by 7,989 shares to 44,453 shares, valued at $6.10M in 2017Q4, according to the filing. It also reduced its holding in Ishares Msci Japan Ucits Etf by 19,425 shares in the quarter, leaving it with 83,339 shares, and cut its stake in Thermo Fisher Scientific Inc (NYSE:TMO).

PTC Therapeutics, Inc. (NASDAQ:PTCT) Institutional Positions Chart

Leave a Reply

Your email address will not be published. Required fields are marked *